Description
ZILBRYSQ 32.4 MG
First action · last action
2026-03-04 · 2026-04-14
Transactions
2
First transaction's obligation
$30,602
Base + all options value (sum of deltas)
$31,041
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
1
SDVOSB flag on record
No
Parent IDV
36F79725D0227
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2026-03-04+$30,602= $30,602
- Mod P000012026-04-14+$439= $31,041
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2026-03-04 | +$30,602 | $30,602 | ZILBRYSQ 32.4 MG |
| Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2026-04-14 | +$439 | $31,041 | ZILBRYSQ 32.4 MG |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI F3N9Q9TY2BC9)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24526F0346 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $31,041 | FY2026 |
| 36C24526N0727 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $31,041 | FY2026 |
| 36C24526N0666 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $31,041 | FY2026 |
| 36C24526N0574 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $31,041 | FY2026 |
| 36C24526N0526 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $31,041 | FY2026 |
| 36E79726A0005 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
Other recipients under 6505 from 245-NETWORK CONTRACT OFFICE 5 (36C245) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24526N0840 | TAKEDA PHARMACEUTICALS AMERICA, INC. | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $19,139 | FY2026 |
| 36C24526N0839 | TAKEDA PHARMACEUTICALS AMERICA, INC. | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $38,360 | FY2026 |
| 36C24526N0837 | QOL MEDICAL LLC | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $16,945 | FY2026 |
| 36C24526N0834 | GALDERMA LABORATORIES, L.P. | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $16,960 | FY2026 |
| 36C24526N0835 | TAKEDA PHARMACEUTICALS AMERICA, INC. | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $34,605 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C24526N0378_3600_36F79725D0227_3600 · retrieved 2026-09-26.